{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:19:09Z","timestamp":1791231549517,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06284-w","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T06:00:11Z","timestamp":1755928811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term survival of a SMARCA4-deficient undifferentiated thoracic tumor with brain metastasis successfully treated with multimodal treatment: a case report and literature review"],"prefix":"10.1007","volume":"151","author":[{"given":"Yu","family":"Gan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"6284_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244207","author":"M Abdallah","year":"2024","unstructured":"Abdallah M, Voland R, Decamp M, Flickinger J, Pacioles T, Jamil M, Silbermins D, Shenouda M, Valsecchi M, Bir A, Shweihat Y, Bastidas J, Chowdhury N, Kachynski Y, Eldib H, Wright T, Mahdi A, Al-Nusair J, Nwanwene K, Varlotto J (2024) Evaluation of anti-angiogenic therapy combined with immunotherapy and chemotherapy as a strategy to treat locally advanced and metastatic non-small-cell lung cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16244207","journal-title":"Cancers (Basel)"},{"issue":"8","key":"6284_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1158\/2326-6066.CIR-19-0866","volume":"8","author":"S Abou Alaiwi","year":"2020","unstructured":"Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, Spurr LF, Li YY, Li T, Flaifel A, Steinharter JA, Margolis CA, Vokes NI, Du H, Shukla SA, Cherniack AD, Sonpavde G, Haddad RI, Awad MM, Giannakis M, Hodi FS, Liu XS, Signoretti S, Kadoch C, Freedman ML, Kwiatkowski DJ, Van Allen EM, Choueiri TK (2020) Mammalian SWI\/SNF complex genomic alterations and immune checkpoint blockade in solid tumors. Cancer Immunol Res 8(8):1075\u20131084. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0866","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"6284_CR3","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.jtho.2021.03.024","volume":"16","author":"JV Alessi","year":"2021","unstructured":"Alessi JV, Ricciuti B, Spurr LF, Gupta H, Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, Felt KD, Rodig SJ, Cheng ML, Sholl LM, Awad MM (2021) SMARCA4 and other SWItch\/sucrose nonfermentable family genomic alterations in NSCLC: clinicopathologic characteristics and outcomes to immune checkpoint inhibition. J Thorac Oncol 16(7):1176\u20131187. https:\/\/doi.org\/10.1016\/j.jtho.2021.03.024","journal-title":"J Thorac Oncol"},{"issue":"2","key":"6284_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1159\/000515416","volume":"14","author":"N Anzic","year":"2021","unstructured":"Anzic N, Krasniqi F, Eberhardt AL, Tzankov A, Haslbauer JD (2021) Ipilimumab and pembrolizumab mixed response in a 41-year-old patient with SMARCA4-deficient thoracic sarcoma: an interdisciplinary case study. Case Rep Oncol 14(2):706\u2013715. https:\/\/doi.org\/10.1159\/000515416","journal-title":"Case Rep Oncol"},{"issue":"12","key":"6284_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.tig.2020.07.011","volume":"36","author":"RC Centore","year":"2020","unstructured":"Centore RC, Sandoval GJ, Soares LMM, Kadoch C, Chan HM (2020) Mammalian SWI\/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies. Trends Genet 36(12):936\u2013950. https:\/\/doi.org\/10.1016\/j.tig.2020.07.011","journal-title":"Trends Genet"},{"key":"6284_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2020.02.002","volume":"142","author":"OSH Chan","year":"2020","unstructured":"Chan OSH, Lam KC, Li JYC, Choi FPT, Wong CYH, Chang ATY, Mo FKF, Wang Ki, Yeung RMW, Mok TSK (2020) ATOM: a phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI. Lung Cancer 142:41\u201346. https:\/\/doi.org\/10.1016\/j.lungcan.2020.02.002","journal-title":"Lung Cancer"},{"issue":"1","key":"6284_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00428-020-03011-3","volume":"478","author":"K Chatzopoulos","year":"2021","unstructured":"Chatzopoulos K, Boland JM (2021) Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors. Virchows Arch 478(1):21\u201330. https:\/\/doi.org\/10.1007\/s00428-020-03011-3","journal-title":"Virchows Arch"},{"issue":"9","key":"6284_CR8","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1007\/s00330-019-06017-x","volume":"29","author":"A Crombe","year":"2019","unstructured":"Crombe A, Alberti N, Villard N, Pilleul F, Buy X, Le Loarer F, Kind M (2019) Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients. Eur Radiol 29(9):4730\u20134741. https:\/\/doi.org\/10.1007\/s00330-019-06017-x","journal-title":"Eur Radiol"},{"issue":"5","key":"6284_CR9","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jtho.2020.01.002","volume":"15","author":"I Dagogo-Jack","year":"2020","unstructured":"Dagogo-Jack I, Schrock AB, Kem M, Jessop N, Lee J, Ali SM, Ross JS, Lennerz JK, Shaw AT, Mino-Kenudson M (2020) Clinicopathologic characteristics of BRG1-deficient NSCLC. J Thorac Oncol 15(5):766\u2013776. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.002","journal-title":"J Thorac Oncol"},{"key":"6284_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1371379","volume":"15","author":"W Dong","year":"2024","unstructured":"Dong W, Dai A, Wu Z, Wang J, Wu T, Du Y, Tian W, Zheng J, Zhang Y, Wang H, Cai J, Dong S, Zhou Y, Li S, Xiao Z (2024) Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report. Front Immunol 15:1371379. https:\/\/doi.org\/10.3389\/fimmu.2024.1371379","journal-title":"Front Immunol"},{"issue":"6","key":"6284_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/oncolo\/oyac040","volume":"27","author":"J Gantzer","year":"2022","unstructured":"Gantzer J, Davidson G, Vokshi B, Weingertner N, Bougouin A, Moreira M, Lindner V, Lacroix G, Mascaux C, Chenard M-P, Bertucci F, Davidson I, Kurtz J-E, Saut\u00e8s-Fridman C, Fridman WH, Malouf GG (2022) Immune-desert tumor microenvironment in thoracic SMARCA4-deficient undifferentiated tumors with limited efficacy of immune checkpoint inhibitors. Oncologist 27(6):501\u2013511. https:\/\/doi.org\/10.1093\/oncolo\/oyac040","journal-title":"Oncologist"},{"issue":"1","key":"6284_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/icvts\/ivz221","volume":"30","author":"SJ Han","year":"2020","unstructured":"Han SJ, Cho S, Yum S, Kim K, Jheon S (2020) Surgical treatment of pulmonary oligorecurrence after curative resection for non-small-cell lung cancer. Interact Cardiovasc Thorac Surg 30(1):18\u201323. https:\/\/doi.org\/10.1093\/icvts\/ivz221","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"9","key":"6284_CR13","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1200\/JCO.20.03570","volume":"39","author":"NH Hanna","year":"2021","unstructured":"Hanna NH, Robinson AG, Temin S, Baker S Jr., Brahmer JR, Ellis PM, Gaspar LE, Haddad RY, Hesketh PJ, Jain D, Jaiyesimi I, Johnson DH, Leighl NB, Moffitt PR, Phillips T, Riely GJ, Rosell R, Schiller JH, Schneider BJ, Singh N, Spigel DR, Tashbar J, Masters G (2021) Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol 39(9):1040\u20131091. https:\/\/doi.org\/10.1200\/JCO.20.03570","journal-title":"J Clin Oncol"},{"issue":"8","key":"6284_CR14","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/annonc\/mdz160","volume":"30","author":"C Henon","year":"2019","unstructured":"Henon C, Blay JY, Massard C, Mir O, Bahleda R, Dumont S, Postel-Vinay S, Adam J, Soria J-C, Le Cesne A (2019) Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. Ann Oncol 30(8):1401\u20131403. https:\/\/doi.org\/10.1093\/annonc\/mdz160","journal-title":"Ann Oncol"},{"issue":"8","key":"6284_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2217\/imt-2019-0142","volume":"12","author":"Y Iijima","year":"2020","unstructured":"Iijima Y, Sakakibara R, Ishizuka M, Honda T, Shirai T, Okamoto T, Tateishi T, Sakashita H, Tamaoka M, Takemoto A, Kumaki Y, Ikeda S, Miyazaki Y (2020) Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report. Immunotherapy 12(8):563\u2013569. https:\/\/doi.org\/10.2217\/imt-2019-0142","journal-title":"Immunotherapy"},{"issue":"1","key":"6284_CR16","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4(1):e173501. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3501","journal-title":"JAMA Oncol"},{"issue":"1","key":"6284_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12672-023-00639-w","volume":"14","author":"J Jiang","year":"2023","unstructured":"Jiang J, Chen Z, Gong J, Han N, Lu H (2023) Thoracic SMARCA4-deficient undifferentiated tumor. Discov Oncol 14(1):51. https:\/\/doi.org\/10.1007\/s12672-023-00639-w","journal-title":"Discov Oncol"},{"issue":"10","key":"6284_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2217\/imt-2020-0311","volume":"13","author":"H Kawachi","year":"2021","unstructured":"Kawachi H, Kunimasa K, Kukita Y, Nakamura H, Honma K, Kawamura T, Inoue T, Tamiya M, Kuhara H, Nishino K, Mizote Yu, Akazawa T, Tahara H, Kumagai T (2021) Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. Immunotherapy 13(10):799\u2013806. https:\/\/doi.org\/10.2217\/imt-2020-0311","journal-title":"Immunotherapy"},{"issue":"11","key":"6284_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100235","volume":"2","author":"K Kunimasa","year":"2021","unstructured":"Kunimasa K, Okami J, Takenaka S, Honma K, Kukita Y, Nagata S, Kawamura T, Inoue T, Tamiya M, Kuhara H, Nishino K, Tahara H, Kumagai T (2021) Conversion surgery for advanced thoracic SMARCA4-deficient undifferentiated tumor with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin treatment: a case report. JTO Clin Res Rep 2(11):100235. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100235","journal-title":"JTO Clin Res Rep"},{"issue":"11","key":"6284_CR20","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.12998\/wjcc.v11.i11.2521","volume":"11","author":"HJ Kwon","year":"2023","unstructured":"Kwon HJ, Jang MH (2023) SMARCA4-deficient undifferentiated thoracic tumor: a case report. World J Clin Cases 11(11):2521\u20132527. https:\/\/doi.org\/10.12998\/wjcc.v11.i11.2521","journal-title":"World J Clin Cases"},{"issue":"10","key":"6284_CR21","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/ng.3399","volume":"47","author":"F Le Loarer","year":"2015","unstructured":"Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N, Auguste A, Pissaloux D, Boyault S, Paindavoine S, Dechelotte PJ, Besse B, Vignaud JM, Brevet M, Fadel E, Richer W, Treilleux I, Masliah-Planchon J, Devouassoux-Shisheboran M, Zalcman G, Allory Y, Bourdeaut F, Thivolet-Bejui F, Ranchere-Vince D, Girard N, Lantuejoul S, Galateau-Sall\u00e9 F, Coindre JM, Leary A, Delattre O, Blay JY, Tirode F (2015) SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet 47(10):1200\u20131205. https:\/\/doi.org\/10.1038\/ng.3399","journal-title":"Nat Genet"},{"issue":"9","key":"6284_CR22","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee WS, Yang H, Chon HJ, Kim C (2020) Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med 52(9):1475\u20131485. https:\/\/doi.org\/10.1038\/s12276-020-00500-y","journal-title":"Exp Mol Med"},{"issue":"11","key":"6284_CR23","doi-asserted-by":"publisher","first-page":"8663","DOI":"10.1007\/s00432-023-04806-y","volume":"149","author":"Y Lin","year":"2023","unstructured":"Lin Y, Yu B, Sun H, Zhang H, Hu Z, Zhang Y, Wu Z, Sun Si, Zhao X, Yu H, Wu X, Li Y, Wang J, Wang H (2023) Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor. J Cancer Res Clin Oncol 149(11):8663\u20138671. https:\/\/doi.org\/10.1007\/s00432-023-04806-y","journal-title":"J Cancer Res Clin Oncol"},{"key":"6284_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063237","author":"V Longo","year":"2024","unstructured":"Longo V, Catino A, Montrone M, Montagna ES, Pesola F, Marech I, Pizzutilo P, Nardone A, Perrone A, Gesualdo M, Galetta D (2024) Treatment of thoracic SMARCA4-deficient undifferentiated tumors: where we are and where we will go. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25063237","journal-title":"Int J Mol Sci"},{"issue":"8","key":"6284_CR25","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1007\/s00432-022-04359-6","volume":"149","author":"J Luo","year":"2023","unstructured":"Luo J, Ding B, Campisi A, Chen T, Teng H, Ji C (2023) Molecular, clinicopathological characteristics and surgical results of resectable SMARCA4-deficient thoracic tumors. J Cancer Res Clin Oncol 149(8):4455\u20134463. https:\/\/doi.org\/10.1007\/s00432-022-04359-6","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"6284_CR26","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1158\/1535-7163.MCT-21-0433","volume":"20","author":"K Mardinian","year":"2021","unstructured":"Mardinian K, Adashek JJ, Botta GP, Kato S, Kurzrock R (2021) SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy. Mol Cancer Ther 20(12):2341\u20132351. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0433","journal-title":"Mol Cancer Ther"},{"issue":"5\u20136","key":"6284_CR27","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000493335","volume":"62","author":"M Matsushita","year":"2018","unstructured":"Matsushita M, Kuwamoto S (2018) Cytologic features of SMARCA4-deficient thoracic sarcoma: a case report and comparison with other SWI\/SNF complex-deficient tumors. Acta Cytol 62(5\u20136):456\u2013462. https:\/\/doi.org\/10.1159\/000493335","journal-title":"Acta Cytol"},{"issue":"7","key":"6284_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","volume":"17","author":"P Mittal","year":"2020","unstructured":"Mittal P, Roberts CWM (2020) The SWI\/SNF complex in cancer\u2014biology, biomarkers and therapy. Nat Rev Clin Oncol 17(7):435\u2013448. https:\/\/doi.org\/10.1038\/s41571-020-0357-3","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"6284_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","volume":"17","author":"AG Nicholson","year":"2022","unstructured":"Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S, Noguchi M, Papotti M, Rekhtman N, Scagliotti G, van Schil P, Sholl L, Yatabe Y, Yoshida A, Travis WD (2022) The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol 17(3):362\u2013387. https:\/\/doi.org\/10.1016\/j.jtho.2021.11.003","journal-title":"J Thorac Oncol"},{"issue":"6377","key":"6284_CR30","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, Wucherpfennig KW (2018) A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359(6377):770\u2013775. https:\/\/doi.org\/10.1126\/science.aao1710","journal-title":"Science"},{"issue":"4","key":"6284_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/PAS.0000000000001188","volume":"43","author":"R Perret","year":"2019","unstructured":"Perret R, Chalabreysse L, Watson S, Serre I, Garcia S, Forest F, Yvorel V, Pissaloux D, de Thomas Montpreville V, Masliah-planchon J, Lantuejoul S, Brevet M, Blay J-Y, Coindre J-M, Tirode F, Le Loarer F (2019) SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses. Am J Surg Pathol 43(4):455\u2013465. https:\/\/doi.org\/10.1097\/PAS.0000000000001188","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"6284_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jtho.2019.10.023","volume":"15","author":"N Rekhtman","year":"2020","unstructured":"Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, Sauter JL, Kezlarian B, Jungbluth A, Desmeules P, Beras A, Bishop JA, Plodkowski AJ, Gounder MM, Schoenfeld AJ, Namakydoust A, Li BT, Rudin CM, Riely GJ, Jones DR, Ladanyi M, Travis WD (2020) SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol 15(2):231\u2013247. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.023","journal-title":"J Thorac Oncol"},{"issue":"4","key":"6284_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M (2024) Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22(4):249\u2013274. https:\/\/doi.org\/10.6004\/jnccn.2204.0023","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"6284_CR34","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/modpathol.2017.61","volume":"30","author":"JL Sauter","year":"2017","unstructured":"Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Boland JM (2017) SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Mod Pathol 30(10):1422\u20131432. https:\/\/doi.org\/10.1038\/modpathol.2017.61","journal-title":"Mod Pathol"},{"key":"6284_CR35","doi-asserted-by":"publisher","first-page":"1020875","DOI":"10.3389\/fonc.2022.1020875","volume":"12","author":"L Shi","year":"2022","unstructured":"Shi L, Lin L, Ding Y, Zeng Y, Chen X (2022) Case report: A rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure. Front Oncol 12:1020875. https:\/\/doi.org\/10.3389\/fonc.2022.1020875","journal-title":"Front Oncol"},{"issue":"3","key":"6284_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/jjco\/hyad175","volume":"54","author":"Y Shinno","year":"2024","unstructured":"Shinno Y, Ohe Y, Lung Cancer Study Group of the Japan Clinical Oncology, G. (2024) Thoracic SMARCA4-deficient undifferentiated tumor: current knowledge and future perspectives. Jpn J Clin Oncol 54(3):265\u2013270. https:\/\/doi.org\/10.1093\/jjco\/hyad175","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"6284_CR37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/1066896919865944","volume":"28","author":"BD Stewart","year":"2020","unstructured":"Stewart BD, Kaye F, Machuca T, Mehta HJ, Mohammed TL, Newsom KJ, Starostik P (2020) SMARCA4-deficient thoracic sarcoma: a case report and review of literature. Int J Surg Pathol 28(1):102\u2013108. https:\/\/doi.org\/10.1177\/1066896919865944","journal-title":"Int J Surg Pathol"},{"key":"6284_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2006.08.046","author":"H Sugimura","year":"2007","unstructured":"Sugimura H, Nichols FC, Yang P, Allen MS, Cassivi SD, Deschamps C, Pairolero PC (2007) Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg. https:\/\/doi.org\/10.1016\/j.athoracsur.2006.08.046","journal-title":"Ann Thorac Surg"},{"key":"6284_CR39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02075","author":"H Sun","year":"2024","unstructured":"Sun H, Li M, Huang W, Zhang J, Wei S, Yang Y, Li B (2024) Thoracic radiotherapy improves the survival in patients with egfr-mutated oligo-organ metastatic non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: a multicenter, randomized, controlled. Phase III Trial J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.23.02075","journal-title":"Phase III Trial J Clin Oncol"},{"issue":"12","key":"6284_CR40","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/1759-7714.13215","volume":"10","author":"K Takada","year":"2019","unstructured":"Takada K, Sugita S, Murase K, Kikuchi T, Oomori G, Ito R, Hayasaka N, Miyanishi K, Iyama S, Ikeda H, Kobune M, Emori M, Kato J, Hasegawa T (2019) Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: a case report. Thorac Cancer 10(12):2312\u20132315. https:\/\/doi.org\/10.1111\/1759-7714.13215","journal-title":"Thorac Cancer"},{"issue":"1","key":"6284_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s40792-024-02053-y","volume":"10","author":"K Takei","year":"2024","unstructured":"Takei K, Isaka M, Wasa J, Kawata T, Masuda T, Katsumata S, Maeda K, Kojima H, Konno H, Ohde Y (2024) Surgical resection following chemoradiotherapy for thoracic SMARCA4-deficient undifferentiated tumor: a report of two cases. Surg Case Rep 10(1):253. https:\/\/doi.org\/10.1186\/s40792-024-02053-y","journal-title":"Surg Case Rep"},{"issue":"2","key":"6284_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/14737140.2023.2152795","volume":"23","author":"AC Tan","year":"2023","unstructured":"Tan AC, Kobayashi K, Saw SPL, Tan DSW, Lim DW (2023) Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma. Expert Rev Anticancer Ther 23(2):117\u2013120. https:\/\/doi.org\/10.1080\/14737140.2023.2152795","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"6284_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6809","volume":"13","author":"A Wang","year":"2024","unstructured":"Wang A, Jin Y, Cao Z, Lu L, Li Z (2024) Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors. Cancer Med 13(1):e6809. https:\/\/doi.org\/10.1002\/cam4.6809","journal-title":"Cancer Med"},{"key":"6284_CR44","doi-asserted-by":"publisher","first-page":"1399868","DOI":"10.3389\/fonc.2024.1399868","volume":"14","author":"C Yin","year":"2024","unstructured":"Yin C, Liu ZJ, He C, Yu HX (2024) A case of surgically treated non-metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report and literature review. Front Oncol 14:1399868. https:\/\/doi.org\/10.3389\/fonc.2024.1399868","journal-title":"Front Oncol"},{"issue":"1","key":"6284_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01651-y","volume":"15","author":"Y Zeng","year":"2020","unstructured":"Zeng Y, Ni J, Yu F, Zhou Y, Zhao Y, Li S, Guo T, Chu Li, Yang Xi, Chu X, Cai X, Zhu Z (2020) The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease. Radiat Oncol 15(1):207. https:\/\/doi.org\/10.1186\/s13014-020-01651-y","journal-title":"Radiat Oncol"},{"issue":"8","key":"6284_CR46","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.jtho.2020.03.030","volume":"15","author":"H Zhou","year":"2020","unstructured":"Zhou H, Shen J, Liu J, Fang W, Zhang L (2020) Efficacy of immune checkpoint inhibitors in SMARCA4-mutant NSCLC. J Thorac Oncol 15(8):e133\u2013e136. https:\/\/doi.org\/10.1016\/j.jtho.2020.03.030","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06284-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06284-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06284-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:35:30Z","timestamp":1757478930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06284-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["6284"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06284-w","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"14 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted following local legislative and institutional requirements. The patient provided written informed consent for study participation. Written informed consent has also been obtained from the patient to publish any potentially identifiable images or data in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0\u2013.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"234"}}